Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zastaprazan + aspirin
- Development stage
- Phase 1
- Lead developer
- Jeil Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JP-1366 + aspirin is a drug combination consisting of zastaprazan (JP-1366), a novel potassium-competitive acid blocker (P-CAB), and aspirin, a nonsteroidal anti-inflammatory drug (NSAID) and antiplatelet agent. Zastaprazan, developed by Onconic Therapeutics (a subsidiary of Jeil Pharmaceutical), inhibits the gastric H+/K+-ATPase (proton pump) in a potassium-competitive manner to suppress acid secretion. This combination is primarily evaluated in clinical settings to assess pharmacokinetic and pharmacodynamic drug-drug interactions (DDI) and to investigate the potential of zastaprazan in preventing NSAID-induced peptic ulcers, a common complication of long-term aspirin therapy.
- Other names
- zastaprazan + acetylsalicylic acid
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on zastaprazan + aspirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zastaprazan + aspirin.